Scientific paper - Letter
Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?
British Journal of Clinical Pharmacology, 87 (2021), 9; 3632-3633. https://doi.org/10.1111/bcp.14763

Marčec, Robert; Likić, Robert

Cite this document

Marčec, R. & Likić, R. (2021). Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?. British Journal of Clinical Pharmacology, 87. (9), 3632-3633. doi: 10.1111/bcp.14763

Marčec, Robert and Robert Likić. "Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?." British Journal of Clinical Pharmacology, vol. 87, no. 9, 2021, pp. 3632-3633. https://doi.org/10.1111/bcp.14763

Marčec, Robert and Robert Likić. "Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?." British Journal of Clinical Pharmacology 87, no. 9 (2021): 3632-3633. https://doi.org/10.1111/bcp.14763

Marčec, R. and Likić, R. (2021) 'Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?', British Journal of Clinical Pharmacology, 87(9), pp. 3632-3633. doi: 10.1111/bcp.14763

Marčec R, Likić R. Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?. British Journal of Clinical Pharmacology [Internet]. 2021 September [cited 2024 October 07];87(9):3632-3633. doi: 10.1111/bcp.14763

R. Marčec and R. Likić, "Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines — Much ado about nothing?", British Journal of Clinical Pharmacology, vol. 87, no. 9, pp. 3632-3633, September 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:451910. [Accessed: 07 October 2024]

Please login to the repository to save this object to your list.